NantWorks, LLC announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present an analysis on how comprehensive molecular profiling with proteomic and genomic analysis revealed CDK6 as a potential therapeutic target in adenoid cystic carcinoma (ACC).
June 2, 2018
· 3 min read